Market Cap 9.35B
Revenue (ttm) 638.50M
Net Income (ttm) -183.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.69%
Debt to Equity Ratio 1.33
Volume 527,000
Avg Vol 592,902
Day's Range N/A - N/A
Shares Out 51.15M
Stochastic %K 60%
Beta 0.48
Analysts Strong Sell
Price Target $225.30

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 332 3241
Fax: 212 320 0245
Address:
One World Trade Center, 29th Floor, New York, United States
Georgejj
Georgejj Apr. 25 at 11:52 AM
$AXSM https://www.psychiatrictimes.com/view/the-curious-story-of-sigma-1-receptors Good luck and GOD bless,
0 · Reply
billions310
billions310 Apr. 25 at 10:54 AM
$AXSM For those of you who have had direct experience with Alzheimer's patients, and also the respectful care takers, fully understand that currently there is no remedy for the patients agitation with exception of heavy duty narcotics. Ive read some people discuss labeling takes time. Labelling ha? This is not a cure for Alzheimers, and AXSM only is providing a remedy to the agitation (side effect) of this disease. The moderate to severe Alzheimers patients eventually start playing with their feces and it ends their lives when brain fails to direct body to swallow food. Now why the wait in approving a drug that showed safety and efficacy in the first three phases (only three are typically required, the purpose of the fourth wasn't to examine the efficacy or safety) clinical trials! this is where we should stand up to fight the BS Bureaucracy.
1 · Reply
WAJeff
WAJeff Apr. 25 at 5:42 AM
$AXSM Will probably get back in here
1 · Reply
Zerocool510
Zerocool510 Apr. 24 at 11:52 PM
$AXSM we were at 186,000 shares traded then itjumped over 500,000 after hours. Finally the big spike we been waiting for.
2 · Reply
Georgejj
Georgejj Apr. 24 at 7:57 PM
$AXSM A Review of Data on AXS-05 for Alzheimer Disease Agitation in Advance of Next Week's PDUFA Date https://www.psychiatrictimes.com/view/a-review-of-data-on-axs-05-for-alzheimer-disease-agitation-in-advance-of-next-weeks-pdufa-date Good luck and GOD bless,
0 · Reply
Georgejj
Georgejj Apr. 24 at 7:55 PM
$AXSM On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results from its Phase III MOVEMENT (NCT04068051) trial for its acute migraine therapy Symbravo (meloxicam + rizatriptan) focused on patient-reported outcomes. https://www.clinicaltrialsarena.com/analyst-comment/aan-2026-new-data-demonstrates-symbravos-cumulative-benefit-for-acute-migraine/?cf-view Good luck and GOD bless,
0 · Reply
Georgejj
Georgejj Apr. 24 at 7:22 PM
$AXSM Expect next week to be a GREAT WEEK for AXSM stock!!! Good luck and GOD bless,
0 · Reply
Vakeshka
Vakeshka Apr. 24 at 7:13 PM
$AXSM you all can thank me for my buy this AM driving a major share price reversal :-)
1 · Reply
IsabellaDC
IsabellaDC Apr. 24 at 6:14 PM
$AXSM Signaling extension again. :)
1 · Reply
Merlintrader
Merlintrader Apr. 24 at 6:10 PM
$AXSM Axsome Therapeutics ( $AXSM ) — April 24 update, 2026 deep dive: setup to the April 30 PDUFA https://merlintrader.com/axsome-therapeutics-march31-2026-dd/
1 · Reply
Latest News on AXSM
Axsome Therapeutics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 8:00 AM EST - 2 months ago

Axsome Therapeutics Earnings Call Transcript: Q4 2025


FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars

Dec 31, 2025, 10:30 AM EST - 4 months ago

FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars


Axsome Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 6 months ago

Axsome Therapeutics Earnings Call Transcript: Q3 2025


Axsome Therapeutics Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 9 months ago

Axsome Therapeutics Earnings Call Transcript: Q2 2025


Axsome Therapeutics Transcript: R&D Day 2025

Jul 21, 2025, 11:00 AM EDT - 9 months ago

Axsome Therapeutics Transcript: R&D Day 2025


Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

May 5, 2025, 10:41 AM EDT - 1 year ago

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1


Axsome Therapeutics Earnings Call Transcript: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Earnings Call Transcript: Q1 2025


Axsome Therapeutics Earnings Call Transcript: Q4 2024

Feb 18, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Earnings Call Transcript: Q4 2024


Axsome Therapeutics Transcript: FDA Announcement

Jan 31, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Transcript: FDA Announcement


US FDA approves Axsome Therapeutics' migraine drug

Jan 30, 2025, 3:55 PM EST - 1 year ago

US FDA approves Axsome Therapeutics' migraine drug


Axsome Therapeutics Transcript: Study Result

Dec 30, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Transcript: Study Result


Axsome Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Earnings Call Transcript: Q3 2024


Axsome Therapeutics Earnings Call Transcript: Q2 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Earnings Call Transcript: Q2 2024


Axsome Therapeutics Transcript: AGM 2024

Jun 7, 2024, 9:00 AM EDT - 2 years ago

Axsome Therapeutics Transcript: AGM 2024


Axsome Therapeutics Earnings Call Transcript: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Axsome Therapeutics Earnings Call Transcript: Q1 2024


Axsome Therapeutics Earnings Call Transcript: Q4 2023

Feb 20, 2024, 8:00 AM EST - 2 years ago

Axsome Therapeutics Earnings Call Transcript: Q4 2023


Axsome Therapeutics Earnings Call Transcript: Q3 2023

Nov 6, 2023, 8:00 AM EST - 2 years ago

Axsome Therapeutics Earnings Call Transcript: Q3 2023


Axsome Therapeutics Earnings Call Transcript: Q2 2023

Aug 7, 2023, 8:00 AM EDT - 2 years ago

Axsome Therapeutics Earnings Call Transcript: Q2 2023


Axsome Therapeutics Earnings Call Transcript: Q1 2023

May 8, 2023, 8:00 AM EDT - 3 years ago

Axsome Therapeutics Earnings Call Transcript: Q1 2023


Axsome Therapeutics Earnings Call Transcript: Q4 2022

Feb 27, 2023, 8:00 AM EST - 3 years ago

Axsome Therapeutics Earnings Call Transcript: Q4 2022


Axsome Therapeutics Earnings Call Transcript: Q3 2022

Nov 7, 2022, 10:00 AM EST - 3 years ago

Axsome Therapeutics Earnings Call Transcript: Q3 2022


Axsome Therapeutics Transcript: FDA Announcement

Aug 19, 2022, 8:00 AM EDT - 4 years ago

Axsome Therapeutics Transcript: FDA Announcement


Axsome Therapeutics Earnings Call Transcript: Q2 2022

Aug 9, 2022, 8:30 AM EDT - 4 years ago

Axsome Therapeutics Earnings Call Transcript: Q2 2022


Axsome Therapeutics Transcript: Investor Update

Jun 28, 2022, 10:00 AM EDT - 4 years ago

Axsome Therapeutics Transcript: Investor Update


Axsome Therapeutics Earnings Call Transcript: Q1 2022

May 2, 2022, 8:02 AM EDT - 4 years ago

Axsome Therapeutics Earnings Call Transcript: Q1 2022


Axsome Therapeutics Transcript: M&A Announcement

Mar 28, 2022, 8:00 AM EDT - 4 years ago

Axsome Therapeutics Transcript: M&A Announcement


Axsome Therapeutics Earnings Call Transcript: Q4 2021

Mar 1, 2022, 8:00 AM EST - 4 years ago

Axsome Therapeutics Earnings Call Transcript: Q4 2021


Axsome Therapeutics Earnings Call Transcript: Q3 2021

Nov 8, 2021, 8:00 AM EST - 4 years ago

Axsome Therapeutics Earnings Call Transcript: Q3 2021


Axsome Therapeutics Earnings Call Transcript: Q2 2021

Aug 9, 2021, 8:00 AM EDT - 5 years ago

Axsome Therapeutics Earnings Call Transcript: Q2 2021


Axsome Therapeutics Earnings Call Transcript: Q1 2021

May 10, 2021, 8:00 AM EDT - 5 years ago

Axsome Therapeutics Earnings Call Transcript: Q1 2021


Axsome Therapeutics Earnings Call Transcript: Q4 2020

Mar 1, 2021, 8:00 AM EST - 5 years ago

Axsome Therapeutics Earnings Call Transcript: Q4 2020


Axsome Therapeutics Earnings Call Transcript: Q3 2020

Nov 5, 2020, 8:00 AM EST - 5 years ago

Axsome Therapeutics Earnings Call Transcript: Q3 2020


Axsome Therapeutics Transcript: Study Update

Sep 21, 2020, 8:00 AM EDT - 6 years ago

Axsome Therapeutics Transcript: Study Update


Axsome Therapeutics Earnings Call Transcript: Q2 2020

Aug 10, 2020, 8:00 AM EDT - 6 years ago

Axsome Therapeutics Earnings Call Transcript: Q2 2020


Axsome Therapeutics Transcript: AGM 2020

Jun 5, 2020, 9:00 AM EDT - 6 years ago

Axsome Therapeutics Transcript: AGM 2020


Axsome Therapeutics Earnings Call Transcript: Q1 2020

May 8, 2020, 8:00 AM EDT - 6 years ago

Axsome Therapeutics Earnings Call Transcript: Q1 2020


Axsome Therapeutics Transcript: Study Result

Apr 27, 2020, 8:00 AM EDT - 6 years ago

Axsome Therapeutics Transcript: Study Result


Axsome Therapeutics Transcript: Study Result

Apr 6, 2020, 8:00 AM EDT - 6 years ago

Axsome Therapeutics Transcript: Study Result


Axsome Therapeutics Transcript: Study Result

Mar 30, 2020, 8:00 AM EDT - 6 years ago

Axsome Therapeutics Transcript: Study Result


Axsome Therapeutics Earnings Call Transcript: Q4 2019

Mar 12, 2020, 8:00 AM EDT - 6 years ago

Axsome Therapeutics Earnings Call Transcript: Q4 2019


Axsome Therapeutics Transcript: Investor Update

Jan 13, 2020, 8:30 AM EST - 6 years ago

Axsome Therapeutics Transcript: Investor Update


Axsome Therapeutics Transcript: Study Result

Dec 30, 2019, 8:00 AM EST - 6 years ago

Axsome Therapeutics Transcript: Study Result


Axsome Therapeutics Transcript: Study Result

Dec 16, 2019, 8:00 AM EST - 6 years ago

Axsome Therapeutics Transcript: Study Result


Axsome Therapeutics Transcript: Study Result

Dec 3, 2019, 8:00 AM EST - 6 years ago

Axsome Therapeutics Transcript: Study Result


Axsome Therapeutics Transcript: R&D Day 2019

Nov 25, 2019, 9:00 AM EST - 6 years ago

Axsome Therapeutics Transcript: R&D Day 2019


Axsome Therapeutics Earnings Call Transcript: Q3 2019

Nov 7, 2019, 8:00 AM EST - 7 years ago

Axsome Therapeutics Earnings Call Transcript: Q3 2019


Axsome Therapeutics Earnings Call Transcript: Q2 2019

Aug 8, 2019, 8:00 AM EDT - 7 years ago

Axsome Therapeutics Earnings Call Transcript: Q2 2019


Georgejj
Georgejj Apr. 25 at 11:52 AM
$AXSM https://www.psychiatrictimes.com/view/the-curious-story-of-sigma-1-receptors Good luck and GOD bless,
0 · Reply
billions310
billions310 Apr. 25 at 10:54 AM
$AXSM For those of you who have had direct experience with Alzheimer's patients, and also the respectful care takers, fully understand that currently there is no remedy for the patients agitation with exception of heavy duty narcotics. Ive read some people discuss labeling takes time. Labelling ha? This is not a cure for Alzheimers, and AXSM only is providing a remedy to the agitation (side effect) of this disease. The moderate to severe Alzheimers patients eventually start playing with their feces and it ends their lives when brain fails to direct body to swallow food. Now why the wait in approving a drug that showed safety and efficacy in the first three phases (only three are typically required, the purpose of the fourth wasn't to examine the efficacy or safety) clinical trials! this is where we should stand up to fight the BS Bureaucracy.
1 · Reply
WAJeff
WAJeff Apr. 25 at 5:42 AM
$AXSM Will probably get back in here
1 · Reply
Zerocool510
Zerocool510 Apr. 24 at 11:52 PM
$AXSM we were at 186,000 shares traded then itjumped over 500,000 after hours. Finally the big spike we been waiting for.
2 · Reply
Georgejj
Georgejj Apr. 24 at 7:57 PM
$AXSM A Review of Data on AXS-05 for Alzheimer Disease Agitation in Advance of Next Week's PDUFA Date https://www.psychiatrictimes.com/view/a-review-of-data-on-axs-05-for-alzheimer-disease-agitation-in-advance-of-next-weeks-pdufa-date Good luck and GOD bless,
0 · Reply
Georgejj
Georgejj Apr. 24 at 7:55 PM
$AXSM On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results from its Phase III MOVEMENT (NCT04068051) trial for its acute migraine therapy Symbravo (meloxicam + rizatriptan) focused on patient-reported outcomes. https://www.clinicaltrialsarena.com/analyst-comment/aan-2026-new-data-demonstrates-symbravos-cumulative-benefit-for-acute-migraine/?cf-view Good luck and GOD bless,
0 · Reply
Georgejj
Georgejj Apr. 24 at 7:22 PM
$AXSM Expect next week to be a GREAT WEEK for AXSM stock!!! Good luck and GOD bless,
0 · Reply
Vakeshka
Vakeshka Apr. 24 at 7:13 PM
$AXSM you all can thank me for my buy this AM driving a major share price reversal :-)
1 · Reply
IsabellaDC
IsabellaDC Apr. 24 at 6:14 PM
$AXSM Signaling extension again. :)
1 · Reply
Merlintrader
Merlintrader Apr. 24 at 6:10 PM
$AXSM Axsome Therapeutics ( $AXSM ) — April 24 update, 2026 deep dive: setup to the April 30 PDUFA https://merlintrader.com/axsome-therapeutics-march31-2026-dd/
1 · Reply
jensenj71
jensenj71 Apr. 24 at 6:07 PM
$AXSM Seems like we had a crazy Monday many moons ago when we broke $100 .. perhaps we can have another awesome Monday and break into the $200S!
2 · Reply
Mike826_1999
Mike826_1999 Apr. 24 at 5:43 PM
$AXSM Symbravo's best week ever! Week Ending 03/06/26: 1,249 Week Ending 03/13/26: 1,174 Week Ending 03/20/26: 1,298 Week Ending 03/27/26: No Data Week Ending 04/03/26: No Data Week Ending 04/10/26: 1,064 Week Ending 04/17/26: 1,387
2 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Apr. 24 at 5:41 PM
2 · Reply
quickaspeter
quickaspeter Apr. 24 at 5:08 PM
$AXSM A Review of Data on AXS-05 for Alzheimer Disease Agitation in Advance of Next Week's PDUFA Date... https://www.psychiatrictimes.com/view/a-review-of-data-on-axs-05-for-alzheimer-disease-agitation-in-advance-of-next-weeks-pdufa-date
0 · Reply
jlfromli
jlfromli Apr. 24 at 4:59 PM
$AXSM Mid Day Announcement ? 📣
0 · Reply
3day
3day Apr. 24 at 3:37 PM
$AXSM next week and into earnings will be lit
0 · Reply
StB55
StB55 Apr. 24 at 3:17 PM
$AXSM While the XBI is currently trading in the red, AXSM is showing green momentum. If this trend holds through the close with significant volume, look like something is in the air and could signal a major move or news catalyst during after-hours or Monday’s pre-market.
0 · Reply
Bio_investor_
Bio_investor_ Apr. 24 at 3:17 PM
$AXSM Gemini: Here are five concise reasons why AXS-05 makes a case for a clean label: Zero Mortality: No deaths or increased mortality risk in elderly trials. No Geriatric Risks: Avoids common falls, sedation, or cognitive decline. Dopamine-Free: Unique mechanism prevents tremors and metabolic issues. FDA Breakthrough: Recognized for "substantial improvement" in safety. Long-Term Safety: Well-tolerated for 12+ months with low adverse events.
0 · Reply
RiderInTheSky
RiderInTheSky Apr. 24 at 2:47 PM
$AXSM The thing about this stock is that it always ends up going past targets 🎯 and then they get raised again
0 · Reply
jeremytowe2000
jeremytowe2000 Apr. 24 at 2:47 PM
$AXSM let’s get $200 today going into Monday approval and hopefully some big EU partnership following Monday in ER.
1 · Reply
Vakeshka
Vakeshka Apr. 24 at 2:34 PM
$AXSM picked up another 30 shares... out of dry powder now.
1 · Reply
AimSmall
AimSmall Apr. 24 at 2:33 PM
$AXSM Mizuho
1 · Reply